• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Ranitidine, metformin, and topiramate: managing weight gain in a clozapine-treated patient with schizoaffective disorder.雷尼替丁、二甲双胍和托吡酯：治疗使用氯氮平的分裂情感性障碍患者体重增加问题
Prim Care Companion CNS Disord. 2014;16(3). doi: 10.4088/PCC.13l01598.
2
Use of metformin to control clozapine-associated weight gain in an adolescent with schizoaffective disorder.
J Child Adolesc Psychopharmacol. 2010 Apr;20(2):153-7. doi: 10.1089/cap.2010.2022.
3
Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.二甲双胍和托吡酯预防和治疗第二代抗精神病药引起的体重增加的疗效。
Ann Pharmacother. 2010 Apr;44(4):668-79. doi: 10.1345/aph.1M550. Epub 2010 Mar 16.
4
Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study.二甲双胍辅助治疗非糖尿病氯氮平治疗的精神分裂症患者的代谢特征及其停药对体重的影响：一项 24 周、随机、双盲、安慰剂对照研究。
J Clin Psychiatry. 2013 May;74(5):e424-30. doi: 10.4088/JCP.12m08186.
5
Combination treatment of clozapine and topiramate in resistant rapid-cycling bipolar disorder.
Clin Neuropharmacol. 2005 May-Jun;28(3):136-8. doi: 10.1097/01.wnf.0000169731.93065.ef.
6
Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.氯氮平治疗难治性精神分裂症、分裂情感性障碍或精神病性双相障碍患者：一项48个月的自然随访研究。
J Clin Psychiatry. 2003 Apr;64(4):451-8. doi: 10.4088/jcp.v64n0416.
7
Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patient.氯氮平治疗的分裂情感性障碍患者中与莫达非尼相关的体重减轻
Ann Clin Psychiatry. 2005 Apr-Jun;17(2):95-7. doi: 10.1080/10401230590932407.
8
Topiramate and Metformin Are Effective Add-On Treatments in Controlling Antipsychotic-Induced Weight Gain: A Systematic Review and Network Meta-Analysis.托吡酯和二甲双胍是控制抗精神病药物所致体重增加的有效附加治疗方法：一项系统评价和网状Meta分析。
Front Pharmacol. 2018 Nov 28;9:1393. doi: 10.3389/fphar.2018.01393. eCollection 2018.
9
Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study.二甲双胍用于治疗南亚地区精神分裂症或分裂情感性障碍患者抗精神病药物所致体重增加：一项双盲、随机、安慰剂对照研究。
J Psychopharmacol. 2015 Dec;29(12):1255-61. doi: 10.1177/0269881115613519. Epub 2015 Oct 28.
10
CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine.CoMET：一项随机对照试验方案，该试验旨在研究将二甲双胍与氯氮平同时起始使用作为辅助治疗，以减轻新开始使用氯氮平的精神分裂症患者的体重增加并改善代谢综合征。
BMJ Open. 2018 Mar 2;8(3):e021000. doi: 10.1136/bmjopen-2017-021000.

本文引用的文献

1
Prevalence of childhood and adult obesity in the United States, 2011-2012.美国儿童和成人肥胖率，2011-2012 年。
JAMA. 2014 Feb 26;311(8):806-14. doi: 10.1001/jama.2014.732.
2
Weight considerations in psychotropic drug prescribing and switching.精神药物处方和换药中的体重考虑因素。
Postgrad Med. 2013 Sep;125(5):117-29. doi: 10.3810/pgm.2013.09.2706.
3
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.二甲双胍用于超重精神分裂症和分裂情感障碍门诊患者的体重减轻和代谢控制。
Am J Psychiatry. 2013 Sep;170(9):1032-40. doi: 10.1176/appi.ajp.2013.12010127.
4
Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects.氨磺必利治疗精神分裂症的增效作用：临床和代谢效应。
J Clin Psychopharmacol. 2010 Dec;30(6):706-10. doi: 10.1097/jcp.0b013e3181fab67d.
5
The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis.与肥胖和超重相关的合并症发病率：一项系统评价和荟萃分析。
BMC Public Health. 2009 Mar 25;9:88. doi: 10.1186/1471-2458-9-88.
6
Weight gain during a double-blind multidosage clozapine study.一项双盲多剂量氯氮平研究中的体重增加情况。
J Clin Psychopharmacol. 2007 Feb;27(1):22-7. doi: 10.1097/JCP.0b013e31802e513a.
7
Energy expenditure and physical activity in clozapine use: implications for weight management.氯氮平使用中的能量消耗与身体活动：对体重管理的影响。
Aust N Z J Psychiatry. 2006 Sep;40(9):810-4. doi: 10.1080/j.1440-1614.2006.01888.x.
8
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.氯氮平与奥氮平、喹硫平及利培酮对既往使用非典型抗精神病药物治疗无效的慢性精神分裂症患者的疗效比较
Am J Psychiatry. 2006 Apr;163(4):600-10. doi: 10.1176/ajp.2006.163.4.600.
9
Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial.奥氮平治疗患者预防体重增加的营养干预：一项随机对照试验。
Aust N Z J Psychiatry. 2005 Jun;39(6):479-86. doi: 10.1080/j.1440-1614.2005.01607.x.
10
Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model.氯氮平对于精神分裂症是否应继续被限制为三线用药？：一个决策分析模型
J Ment Health Policy Econ. 2004 Jun;7(2):77-85.

Ranitidine, metformin, and topiramate: managing weight gain in a clozapine-treated patient with schizoaffective disorder.

作者信息

Greg Deardorff O, Syed Ahsan, Ames Chelsea J, Yaeger Jaclyn S

机构信息

Fulton State Hospital Pharmacy, Fulton, Missouri.

出版信息

Prim Care Companion CNS Disord. 2014;16(3). doi: 10.4088/PCC.13l01598.

DOI:10.4088/PCC.13l01598
PMID:25317361
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4195633/
Abstract
摘要